te Pick of the Year 2024 by Anil Singhvi - Jubilant Pharmova: Check target price and other details | Zee Business

Pick of the Year 2024 by Anil Singhvi - Jubilant Pharmova: Check target price and other details

Pick of the Year 2024 by Anil Singhvi: The company's projected EBITDA (earnings before interest, taxes, depreciation, and amortization) in FY24 is around Rs 1,300 crore and its market cap is just Rs 7,000 crore.

Pick of the Year 2024 by Anil Singhvi - Jubilant Pharmova: Check target price and other details
Zee Business Managing Editor Anil Singhvi suggested that investors should buy stocks of this company for 1-3 years.

Pick of the Year 2024 by Anil Singhvi: Jubilant Pharmova Ltd, a mid-cap pharmaceuticals company, is the first Pick of the Year 2024. According to Zee Business Managing Editor Anil Singhvi, this pharma share has been underperforming for the past two years and this is the reason it has been selected as the Pick of the Year 2024. 

"We are bullish on pharma share Jubilant Pharmova and one of the reasons behind picking this stock is that it has been underperforming for the last around 2 years. The company makes active pharmaceutical ingredients (APIs) and generic products with a strong foothold in the global market. They have a kind of monopoly in the radiopharma business in the United States," Singhvi said.

The company's projected EBITDA (earnings before interest, taxes, depreciation, and amortization) in FY24 is around Rs 1,300 crore and its market cap is just Rs 7,000 crore. The company has been struggling with new approvals for quite some time and the year 2024 can be a game changer for the company, he said.

"The company is likely to get approval for two new products in FY25 and this will solidify the company's position in the US market and will be a game changer," Zee Business Managing Editor said.

Pick of the Year 2024 by Anil Singhvi - Jubilant Pharmova - Price Target and Duration

Singhvi suggested that investors should buy stocks of this company for 1-3 years. 

"Don't buy in bulk, instead do a SIP on every 10 per cent fall for targets of Rs 720, Rs 865 and Rs 1,200. These are the targets for the next three years," he added.

It is pertinent to mention that the company's Radiopharma business received ANDA approval for Technetium Sulfur Colloid Injection in November last year. This approval is effective November 9, 2023.

Written By: ZeeBiz WebTeam
Updated: Mon, Jan 01, 2024
12:31 pm
New Delhi, ZeeBiz WebDesk
RELATED NEWS
Anil Singhvi strategy January 29: Important levels to track in Nifty50, Nifty Bank today Anil Singhvi strategy January 29: Important levels to track in Nifty50, Nifty Bank today
Anil Singhvi strategy January 25: Important levels to track in Nifty50, Nifty Bank today Anil Singhvi strategy January 25: Important levels to track in Nifty50, Nifty Bank today
Anil Singhvi strategy January 24: Important levels to track in Nifty50, Nifty Bank today Anil Singhvi strategy January 24: Important levels to track in Nifty50, Nifty Bank today
Anil Singhvi strategy January 23: Important levels to track in Nifty50, Nifty Bank today Anil Singhvi strategy January 23: Important levels to track in Nifty50, Nifty Bank today
Anil Singhvi strategy January 20: Important levels to track in Nifty50, Nifty Bank today Anil Singhvi strategy January 20: Important levels to track in Nifty50, Nifty Bank today

By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.

x